A review of biosensor technologies for blood biomarkers toward monitoring cardiovascular diseases at the point-of-care

Ouyang, Mengxing; Tu, Dandan; Ts, Lin; Sarwar, Mehenur; Bhimaraj, Arvind; Li, Chen-Zhong; Coté, Gerard L.; Carlo, Dino Di

doi:10.1016/j.bios.2020.112621

Cited by 106 publications

(66 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biosensors are chemical sensors that utilize biomolecules as the target recognizing component and a transducer that produce an identifiable signal through their interaction [1,2]. In the case of electrochemical biosensors (ECBs), the transducer converts the chemical signal to an electrical signal that allows for qualitative and quantitative identification of the target biomolecules [1,[3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing

et al. 2020

View full text Add to dashboard Cite

With the rise in public health awareness, research on point-of-care testing (POCT) has significantly advanced. Electrochemical biosensors (ECBs) are one of the most promising candidates for the future of POCT due to their quick and accurate response, ease of operation, and cost effectiveness. This review focuses on the use of metal nanoparticles (MNPs) for fabricating ECBs that has a potential to be used for POCT. The field has expanded remarkably from its initial enzymatic and immunosensor-based setups. This review provides a concise categorization of the ECBs to allow for a better understanding of the development process. The influence of structural aspects of MNPs in biocompatibility and effective sensor design has been explored. The advances in MNP-based ECBs for the detection of some of the most prominent cancer biomarkers (carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), Herceptin-2 (HER2), etc.) and small biomolecules (glucose, dopamine, hydrogen peroxide, etc.) have been discussed in detail. Additionally, the novel coronavirus (2019-nCoV) ECBs have been briefly discussed. Beyond that, the limitations and challenges that ECBs face in clinical applications are examined and possible pathways for overcoming these limitations are discussed.

show abstract

Section: Introductionmentioning

confidence: 99%

Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Detecting and quantifying biomarkers enables disease monitoring, diagnostics, and risk assessment. Recent studies have involved specific biomarkers for assessing preterm birth risk [ 1 ], diagnosing cardiovascular disease [ 2 ], monitoring drug side effects [ 3 ], and so on. Many diseases and conditions require rapid treatment, so researchers are developing tests for biomarkers that are usable at the point-of-care (POC) [ 4 ], where the test can be performed on-site with sometimes limited resources.…”

Section: Introductionmentioning

confidence: 99%

Advances in multiplex electrical and optical detection of biomarkers using microfluidic devices

Mitchell

Esene

2021

Anal Bioanal Chem

View full text Add to dashboard Cite

Graphical abstract Microfluidic devices can provide a versatile, cost-effective platform for disease diagnostics and risk assessment by quantifying biomarkers. In particular, simultaneous testing of several biomarkers can be powerful. Here, we critically review work from the previous 4 years up to February 2021 on developing microfluidic devices for multiplexed detection of biomarkers from samples. We focus on two principal approaches: electrical and optical detection methods that can distinguish and quantify biomarkers. Both electrical and spectroscopic multiplexed detection strategies are being employed to reach limits of detection below clinical sample levels. Some of the most promising strategies for point-of-care assays involve inexpensive materials such as paper-based microfluidic devices, or portable and accessible detectors such as smartphones. This review does not comprehensively cover all multiplexed microfluidic biomarker studies, but rather provides a critical evaluation of key work and suggests promising prospects for future advancement in this field. Electrical and optical multiplexing are powerful approaches for microfluidic biomarker analysis.

show abstract

“…Nowadays, CRP determination is performed by a variety of immunochemical methods [11,12], such as immunoturbidimetric assays [13], enzyme-linked immunosorbent assays [14], chemiluminescence [15] and fluorescence immunoassays [16]. These methods provide high sensitivity and accuracy; however, because they require special equipment and skilled personnel, they are performed mainly at hospitals' central laboratories, which might lead to increased workflow and delays in the delivery of tests results [17,18]. Consequently, the current challenge in diagnostics field is to overcome the limitations of conventional techniques by the development of methods and devices that can provide fast and reliable quantitative results at the Point-of-Care (PoC).…”

Section: Introductionmentioning

confidence: 99%

“…To this direction, different types of biosensors [12,18,[22][23][24], based mainly on electrochemical [25][26][27] or optical transducers [28][29][30], have been proposed for CRP determination. Furthermore, portable and bench-top analyzers are commercially available and provide very fast CRP detection [12,17,31].…”

Section: Introductionmentioning

confidence: 99%

Development of a Point-of-Care System Based on White Light Reflectance Spectroscopy: Application in CRP Determination

et al. 2021

View full text Add to dashboard Cite

The development of methods and miniaturized systems for fast and reliable quantitative determinations at the Point-of-Care is a top challenge and priority in diagnostics. In this work, a compact bench-top system, based on White Light Reflectance Spectroscopy, is introduced and evaluated in an application with high clinical interest, namely the determination of C-Reactive protein (CRP) in human blood samples. The system encompassed all the necessary electronic and optical components for the performance of the assay, while the dedicated software provided the sequence and duration of assay steps, the reagents flow rate, the real-time monitoring of sensor response, and data processing to deliver in short time and accurately the CPR concentration in the sample. The CRP assay included two steps, the first comprising the binding of sample CRP onto the chip immobilized capture antibody and the second the reaction of the surface immunosorbed CRP molecules with the detection antibody. The assay duration was 12 min and the dynamic range was from 0.05 to 200 μg/mL, covering both normal values and acute inflammation incidents. There was an excellent agreement between CRP values determined in human plasma samples using the developed device with those received for the same samples by a standard diagnostic laboratory method.

show abstract

A review of biosensor technologies for blood biomarkers toward monitoring cardiovascular diseases at the point-of-care

Cited by 106 publications

References 100 publications

Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing

Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing

Advances in multiplex electrical and optical detection of biomarkers using microfluidic devices

Development of a Point-of-Care System Based on White Light Reflectance Spectroscopy: Application in CRP Determination

Contact Info

Product

Resources

About